Glaukos Announces Participation in Oppenheimer Healthcare Conference
Glaukos Corporation (NYSE: GKOS) announced its management's virtual participation in the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 3:10 p.m. EDT. This event will be available via live and archived webcast on Glaukos' Investors website. Glaukos specializes in medical technology and pharmaceuticals for treating glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with devices like the iStent series.
- Participation in a notable healthcare conference may enhance visibility and reputation.
- Glaukos has a strong portfolio of innovative devices and therapies for eye diseases.
- None.
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021, at 3:10 p.m. EDT.
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in 2012, its next-generation iStent inject® device in the United States in 2018 and most recently, its iStent inject W device in the United States in 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005097/en/
FAQ
What is Glaukos Corporation's stock symbol?
When is Glaukos participating in the Oppenheimer Healthcare Conference?
How can I watch Glaukos' presentation at the conference?
